ANI Pharmaceuticals, Inc. (ANIP) stock analysis

Healthcare · Drug Manufacturers - Specialty & Generic

From the 10-K filed 2026-02-27

How it makes money

It earns revenue by developing, manufacturing, and commercializing therapeutics across its Rare Disease, Generics, and Brands businesses.

The company operates across three distinct segments: Rare Disease, Generics, and Brands. Its generics portfolio includes more than 120 products with diverse indications, supplemented by internal research, product acquisitions, and distribution agreements. Profits are driven by successfully commercializing approved therapeutics and expanding its product offerings through new product launches, which are expected to yield approximately 10 to 15 new product launches per year.

What protects it: the moat

It protects its market position through patents, regulatory approvals, and intellectual property, though management notes risks from patent expirations.

Management asserts that intellectual property and marketing authorizations protect its branded products. However, the company faces distinct threats to these defenses, including the potential near- to medium-term expiration of patents protecting key aspects of products such as ILUVIEN and YUTIQ, as well as the risk that it may fail to protect its intellectual property in the U.S. and foreign countries.

What growth costs

It reinvests through R&D efforts, acquisitions of businesses and product rights, and capital expenditures for its manufacturing facilities.

The company incurs significant growth and maintenance costs by acquiring businesses, Abbreviated New Drug Applications, New Drug Applications, and product rights. It also expects to spend significant resources on research and development efforts. Additionally, it operates and maintains three pharmaceutical manufacturing facilities located in Baudette, Minnesota and East Windsor, New Jersey, alongside financing activities such as term loans and convertible notes.

What could damage it

Production interruptions at its manufacturing facilities could prevent it from delivering products on time and impair its earnings.

The company relies heavily on its own manufacturing facilities to produce its therapeutics. If production at any or all of its three current manufacturing facilities is interrupted, it could cause the company to fail to deliver products on a timely basis, directly undermining its commercial operations and financial results.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Princeton, New Jersey.

Other companies in Drug Manufacturers - Specialty & Generic